Featured Education

On Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Screening and Management of OSA
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape. Explore the 3-part on-demand series, Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health. This collaborative effort, in conjunction with local AAFP Chapter meetings, provides expert guidance and clinical best practices for screening, managing, monitoring, and treating patients with OSA
Bridging the Gap to Reach Treatment Goals in DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment. Join us for this educational Med Table Talk® LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers. This taped satellite symposium was derived from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR® on February 18, 2023.
Build Your Own Case Study | From Evidence to Practice: Enhancing T2D Outcomes with Informed Approaches on Obesity
The tie between type 2 diabetes (T2D) and overweight/obesity is a significant global public health issue, supported by decades of extensive research. Despite formal clinical guidelines recommendations in addressing both diseases, the initiation or intensification of therapies that improve glycemic control and achieve weight reduction targets are slowly adopted into clinical practice, particularly for patients with T2D. Given the overlap of these two conditions, it is imperative that healthcare providers worldwide align clinical practice with evidence-based guidelines and the latest clinical findings using newer agents to treat both diseases.
Understanding the Impact of Weight on T2D Outcomes
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Integrating Novel Therapies in Hemophilia in the Midst of Bridging Health Inequities
As the treatment armamentarium for patients with hemophilia continues to expand, there is an urgent need for healthcare providers to stay up-to-date on the latest advances so that they are prepared to integrate them into clinical practice. To bridge this gap, this interactive educational activity will provide a review of the science surrounding new and emerging hemophilia treatments and their mechanisms of action; recent safety and efficacy data from key clinical trials; and novel dosing strategies to mitigate adverse events. Engaging case-based discussions and insights on addressing common patient barriers and clinical challenges will be explored by expert faculty, including a guest spotlight offering the early perspective.  Thus, this educational initiative is designed to equip providers with the necessary tools to effectively navigate new and novel therapies, overcome patient-level barriers, and optimize adherence for improved patient outcomes.
Scroll to Top